COMPANY UPDATE

May 2025

To Our Shareholders, Employees & Partners:

We have enjoyed a strong start to the year!

Our portfolio of FDA-approved brands delivered combined revenues of $11.7 million during the first quarter, a 38% increase over the prior year. As a result, we generated a net profit of $1.26 million for the quarter and adjusted earnings of $2.4 million. Our balance sheet also improved with $70 million in total assets, including $15 million in cash, along with a significant decrease in debt resulting in total liabilities of $42 million and shareholders' equity of $29 million.

In February, we announced top-line results from the Phase II study evaluating our **ifetroban** product candidate in patients with **Duchenne muscular dystrophy** (DMD):

- This marks a breakthrough for these patients, as it's the first successful Phase II study specifically targeting the cardiac complications of their condition!
- These study results were selected for a late-breaking presentation in March at the *Muscular Dystrophy Association*'s *Clinical & Scientific Conference*. That platform allowed us to share our promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease.
- Next steps for our DMD program include further data analysis and completion of a full study report in preparation for an end-of-Phase-2 meeting with the FDA to determine next steps associated with the product's development and commercialization.

Meanwhile, we were delighted to learn that our potent antibiotic **Vibativ®** received approval from the regulatory authorities in China! That milestone provides us with access to the world's second-largest pharmaceutical market – and we look forward to the launch of our product there expected later this year.

At *Cumberland Emerging Technologies* (CET), we continue to operate the *Nashville Life Sciences Center*, a vibrant biomedical incubator that houses our formulation laboratories. CET is also advancing the development of a new product we previously announced, which is designed to detect the source of a patient's gastrointestinal bleeding.

We are entering an exciting time for our Company! We remain in the early stages of capitalizing on numerous opportunities and expect our momentum to continue.

Our ongoing success can be driven by growth from our approved brands, expanded international partnerships, progress in our clinical development programs and the potential addition of select acquisitions. Importantly, Cumberland remains in a solid financial position, enabling us to execute our strategy and objectives.

I'd like to close by recognizing and thanking our Cumberland team for their dedicated efforts in advancing our mission: *working together to provide unique products that improve the quality of patient care*.

We look forward to sharing further developments through additional updates during the remainder of the year.

All the best,

Please see our corporate website at www.cumberlandpharma.com for links to our product websites for full prescribing and safety information on our brands and for our SEC filings that contain the risk factors associated with our business.